# Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

> **NCT01951326** · PHASE3 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 331 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** RHB-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01951326
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2018-05
- **Final completion:** 2019-08
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951326, "Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01951326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*